New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
06:38 EDTACT, MS, FRX, GSMorgan Stanley, Goldman said to switch fees for deal credit, Bloomberg says
Morgan Stanley (MS) and Goldman Sachs (GS) both decided last month that it was worth losing millions of dollars in fees to get credit on the $25B sale of Forest Laboratories (FRX) to Actavis (ACT), according to Bloomberg, citing four people with knowledge of the matter. The sources say that neither investment bank actually had a role on the deal. Reference Link
News For MS;GS;FRX;ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 19, 2015
11:53 EDTMS, GSU.S. banks face headwinds in unloading oil loans, WSJ says
Subscribe for More Information
06:42 EDTGSAllianz hedges stake in China Pacific Insurance, Reuters says
Subscribe for More Information
06:06 EDTGSSunrun powers up for IPO later this year, WSJ reports
Sunrun, a solar-energy company, is said to be working with Credit Suisse (CS) and Goldman Sachs (GS) on a potential IPO for later this year, sources tell The Wall Street Journal, which adds that the company was valued at $1.3B as of March 2014. Other solar companies that have gone public in recent years include residential solar installers like Vivint Solar (VSLR), backed by Blackstone (BX), and SolarCity (SCTY), backed by Tesla's (TSLA) Elon Musk. Reference Link
March 18, 2015
08:50 EDTACTActavis price target raised to $373 from $286 at BMO Capital
Subscribe for More Information
07:27 EDTGSFreeport seeks funding from Blackstone, Apollo, Reuters says
Freeport McMoRan (FCX) has hired Goldman Sachs (GS) and Barclays (BCS) to find private equity firms willing to finance certain of its energy projects and asset developments, reports Reuters, citing people familiar with the matter. Freeport is in talks with Blackstone (BX), Apollo (APO), and Warburg Pincus about a potential partnership. The sources say the firm may be seeking "several billion dollars," though discussions are in "very early" stages. Reference Link
06:09 EDTGSGoldman Sachs prices 6M shares of specialty lending arm, WSJ reports
According to a source, late yesterday, Goldman Sachs priced 6M shares of Goldman Sachs BDC, its specialty lending arm, at $20 per share with the shares set to begin trading today, The Wall Street Journal reports. Shares of Goldman Sachs BDC will trade under the ticker symbol "GSBD." Reference Link
March 17, 2015
09:19 EDTACTActavis reinstated with a Conviction Buy at Goldman
Subscribe for More Information
09:13 EDTACTActavis says Allergan CEO not joining combined company board
Subscribe for More Information
08:59 EDTACTActavis sees combined annual pro forma revenues of over $23B in 2015
Subscribe for More Information
08:58 EDTACTActavis sees double digit accretion to adjusted EPS within first 12 months
08:58 EDTACTActavis says will 'immediately begin implementing' integration plans
Subscribe for More Information
08:57 EDTACTActavis completes acquisition of Allergan
Actavis plc (ACT) announced that it has completed the acquisition of Allergan (AGN) in a cash and equity transaction valued at approximately $70.5B. The combination creates one of the world’s top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23B anticipated in 2015. Actavis continues to expect the transaction to generate double-digit accretion to non-GAAP earnings within the first 12 months, including approximately $1.8B in operating and financial synergies to be realized within one year following the close. These synergies exclude any additional revenue or manufacturing synergies, and are in addition to the $475M of annual savings previously announced by Allergan in connection with Project Endurance. Actavis further expects to generate strong operating cash flow in excess of $8B in 2016, which would enable the company to rapidly de-lever the balance sheet.
08:56 EDTACTActavis completes Allergan acquisition valued at $70.5B
Subscribe for More Information
March 16, 2015
18:38 EDTACTAmerican Airlines to replace Allergan in S&P 500 as of 3/20 close
Subscribe for More Information
16:10 EDTACTActavis receives FDA approval for VIIBRYD 20mg once daily
Subscribe for More Information
13:05 EDTMSMorgan Stanley's quarter not shaping up to be strong one, says Rafferty Capital
Rafferty Capital's Dick Bove said Morgan Stanley's current quarter is not shaping up to be a strong one. Bove said industry trade data from the NY Federal Reserve Bank is not that encouraging with fall offs in numbers in key categories. The analyst believes trading is flat to down overall in the quarter and investment banking its not fairing much better. Bove still views Morgan Stanley among his top picks for 2015 despite near-term issues.
12:33 EDTMSMorgan Stanley may be challenged in quarter, says Rafferty Capital
Subscribe for More Information
10:22 EDTACTEuropean Commission clears Actavis' pending acquisition of Allergan
Subscribe for More Information
March 13, 2015
17:33 EDTACTS&P announces changes to S&P 100 Index
Subscribe for More Information
08:03 EDTACTActavis receives FDA approval SAPHRIS for pediatric patients
Actavis announced that the FDA has approved its supplemental new drug application for SAPHRIS as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients. SAPHRIS is the only atypical antipsychotic treatment option with a sublingual formulation. The FDA approval of SAPHRIS is based on the results of a 3-week monotherapy trial in 403 pediatric patients, of which 302 pediatric patients received SAPHRIS twice daily in doses of either 2.5 mg, 5 mg or 10 mg. SAPHRIS was shown to demonstrate improvement in Young Mania Rating Scale total score and Clinical Global Impression-Bipolar Severity of Illness overall score versus placebo in a pediatric clinical trial.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use